Halozyme Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was USD 102 million compared to USD 121.7 million a year ago. Net income was USD 66.77 million compared to USD 73.16 million a year ago.

Basic earnings per share from continuing operations was USD 0.48 compared to USD 0.54 a year ago. Diluted earnings per share from continuing operations was USD 0.46 compared to USD 0.5 a year ago.